WALTHAM, Mass. - Syndax Pharmaceuticals (NASDAQ:SNDX), a developer of cancer therapies, today announced the immediate appointment of Steven Closter as Chief Commercial Officer. Closter succeeds Steve Sabus, who is departing for personal reasons. This change comes as Syndax prepares for two significant product launches anticipated in 2024.
Steven Closter, with over three decades of commercial experience in the biopharmaceutical sector, will oversee the company's commercial strategy and operations. His background includes a variety of senior roles at Sunovion Pharmaceuticals and nearly 20 years at Forest Laboratories, later Allergan (NYSE:AGN). He holds a Bachelor of Science from Cornell University and an MBA from NYU Stern School of Business.
Michael A. Metzger, CEO of Syndax, expressed confidence in Closter's ability to lead the commercial organization during a critical transition period. Metzger also acknowledged the contributions of Steve Sabus in establishing a strong foundation for the company's commercial strategy.
Closter's career has been marked by the successful launch and marketing of over a dozen products and indication expansions, particularly in neurology, psychiatry, and primary care. At Syndax, he aims to drive the launch of revumenib and axatilimab, therapies that are expected to be first and best in their class for treating cancer.
Syndax's pipeline highlights include revumenib, a selective inhibitor of the menin-KMT2A interaction, and axatilimab, a monoclonal antibody targeting the CSF-1 receptor. The company's progress in developing these therapies is part of its broader mission to deliver novel treatments for cancer and fibrotic diseases.
This announcement contains forward-looking statements regarding the anticipated product launches and the potential impact of Steven Closter's leadership. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.
The information in this article is based on a press release statement from Syndax Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.